Amgen, Inc. (NASDAQ:AMGN) updated its FY16 earnings guidance on Thursday. The company provided EPS guidance of $10.60-11.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $10.64, MarketBeat reports. The company issued revenue guidance of $22.0-22.5, compared to the consensus revenue estimate of $22.20 billion.

AMGN has been the subject of several analyst reports. BTIG Research initiated coverage on shares of Amgen in a research report on Thursday, January 7th. They set a sell rating and a $135.00 price target for the company. JPMorgan Chase & Co. reiterated a neutral rating on shares of Amgen in a research report on Thursday, October 29th. Vetr upgraded shares of Amgen from a hold rating to a strong-buy rating and set a $184.24 price target for the company in a research report on Monday, November 30th. Morgan Stanley lifted their price target on shares of Amgen to $160.00 in a research report on Thursday, October 29th. Finally, Piper Jaffray reiterated an overweight rating and set a $200.00 price target on shares of Amgen in a research report on Thursday, October 29th. One research analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the stock. Amgen has a consensus rating of Buy and an average price target of $184.88.

Amgen, Inc. (NASDAQ:AMGN) traded down 1.41% during mid-day trading on Thursday, reaching $148.35. 4,240,716 shares of the company’s stock traded hands. The stock has a market cap of $111.90 billion and a P/E ratio of 17.71. Amgen, Inc. has a 12 month low of $130.09 and a 12 month high of $181.81. The company has a 50 day moving average price of $156.85 and a 200-day moving average price of $157.03.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, January 28th. The medical research company reported $2.61 earnings per share for the quarter, beating analysts’ consensus estimates of $2.29 by $0.32. During the same period in the prior year, the company posted $2.16 EPS. The firm had revenue of $5.54 billion for the quarter, compared to analyst estimates of $5.53 billion. The business’s revenue for the quarter was up 3.8% compared to the same quarter last year. On average, analysts anticipate that Amgen, Inc. will post $10.08 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 8th. Shareholders of record on Tuesday, February 16th will be given a dividend of $1.00 per share. This is an increase from Amgen’s previous quarterly dividend of $0.47. This represents a $4.00 dividend on an annualized basis and a yield of 2.70%. The ex-dividend date is Thursday, February 11th.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.

12 Month Chart for NASDAQ:AMGN

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.